Skip to content

Acupuncture Versus Sham for Radiotherapy-Induced Emesis

Acupuncture Compared To Sham With a Placebo-Needle in Radiotherapy-Induced Nausea - a Randomised Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00621660
Enrollment
237
Registered
2008-02-22
Start date
2004-01-31
Completion date
2007-03-31
Last updated
2008-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Vomiting

Keywords

Acupuncture therapy, Cancer, Emesis, Expectations, Placebo

Brief summary

The aim of this study is to evaluate if acupuncture prevents or reduces nausea or vomiting during radiotherapy

Detailed description

Treatment with acupuncture is, despite sometimes unclear evidence, increasing in cancer care. Acupuncture is used for indications such as pain and nausea, but for radiotherapy (RT) induced nausea it is still an unexplored treatment. For evaluation of the method, the use of sham acupuncture as a control treatment provides a tool resembling placebo for drugs. The aim of the studt is therefore to investigate whether acupuncture reduces nausea caused by radiotherapy in a patient group with a \>50% risk of experiencing the symptoms (abdominal or pelvic region). Patients are randomised to invasive acupuncture (IA) or placebo acupuncture (PA) 30 min, 2-3 times/week during the whole RT period. IA is administered bilaterally to the point PC6 using an invasive needle and PA with a needle, which looks identical but is not pointed and is not fixed in its handle. When this comes into contact with the surface of the skin and gives a feeling of penetration it glides upwards in its handle and is therefore shortened, which gives an illusion that the needle has entered the tissue. Nausea and vomiting is documented in diaries and questionnaires under the entire treatment period as well as two and four weeks after radiotherapy.

Interventions

PROCEDUREAcupuncture

Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred.

PROCEDURESham

Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.

Sponsors

Swedish Cancer Society
CollaboratorOTHER
Ostergotland County Council, Sweden
CollaboratorOTHER
Vardalinstitutet The Swedish Institute for Health Sciences
CollaboratorOTHER
Cancer & Traffic Injury Fund
CollaboratorUNKNOWN
University Hospital, Linkoeping
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients of at least 18 years of age * with gynaecologic-, anal-, rectal-, colon-, ventricle-, pancreatic- or testicular tumours * willing to give their informed consent * able to take part in the entire treatment and data collection procedure * had planned radiation over an abdominal and/or pelvic field (with or without concomitant chemotherapy) with the volume of at least 800 cm3 and a dose of at least 25 Gy.

Exclusion criteria

* use of antiemetic treatment or persistent nausea within 24 hours prior to the start of radiotherapy * ever received acupuncture against nausea, or during the last year received acupuncture for any indication.

Design outcomes

Primary

MeasureTime frame
Number of patients with at least one episode of nausea during the whole radiotherapy treatment periodThe radiotherapy treatment period (md 5 weeks)

Secondary

MeasureTime frame
Secondary outcome measures are the summed number of days with nausea, intensity of nausea, number of patients and summed number of days with vomiting, belief in the antiemetic effects and interest in receiving needling in the futureFrom acupunture start until 4 weeks after treatment stopped

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026